TET2 and MEG3 Promoter Methylation is Associated with Acute Myeloid Leukemia in a Hainan Population

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Apr 15

PMID 28407691

Citations 19

Authors

Hongxia Yao

Mengling Duan

Lie Lin

Congming Wu

Xiangjun Fu

Hua Wang

Li Guo

Wenting Chen

Li Huang

Dan Liu

Ruo Rao

Shuwen Wang

Yipeng Ding

Affiliations

Soon will be listed here.

Abstract

The promoter of MEG3, which encodes the long non-coding RNA (lncRNA) MEG3, is often hypermethylated in acute myeloid leukemia (AML). Additionally, the Tet methylcytosine dioxygenase 2 gene (TET2) is frequently inactivated, which can lead to impaired DNA methylation and promote AML development. We examined the association between TET2 and MEG3 promoter hypermethylation in Hainan patients with AML. The expression of MEG3, TET2, miR-22-3p, and miR-22-5p was assessed in bone marrow samples from AML patients and healthy controls using real-time quantitative PCR. Using Sequenom MassARRAY technology, we compared MEG3 promoter methylation in AML patients and healthy controls. MEG3 expression was lower in AML patients than in the controls (P = 0.136). Moreover, there was greater methylation of MEG3 promoter in the AML patients than the controls (P < 0.05). Methylation of the MEG3 promoter correlated negatively with TET2 expression (P < 0.05, r < 0). Likewise there was a negative correlation between TET2 activity and MEG3 promoter methylation (P < 0.05, r < 0). These results suggest that hypermethylation of the MEG3 promoter in AML may result from decreased TET2 activity. These data provide insight into the molecular mechanisms underlying AML development and progression.

Citing Articles

Combined replacement of lnc-MEG3 and miR-155 elicit tumor suppression in multiple myeloma.

El-Khazragy N, Abdelrahman S, Darwish A, Hemida E Epigenomics. 2025; 17(3):167-177.

PMID: 39815805 PMC: 11816889. DOI: 10.1080/17501911.2025.2453413.

Lower Levels of TET2 Gene Expression, with a Higher Level of TET2 Promoter Methylation in Patients with AML; Evidence for the Role of Aberrant Methylation in AML Pathogenesis.

Ghasemi B, Ahmadi J, Zaker F, Tabatabaei T, Kiani-Zadeh M, Kazemi A Indian J Hematol Blood Transfus. 2024; 40(1):52-60.

PMID: 38312186 PMC: 10831019. DOI: 10.1007/s12288-023-01673-y.

The emerging role of microRNA-22 in the Leukemia: experimental and clinical implications.

Xia J, Bu C, Zhang B, Wang X, Chen Y, Li T Mol Biol Rep. 2023; 51(1):12.

PMID: 38085373 DOI: 10.1007/s11033-023-08922-3.

The lncRNA epigenetics: The significance of m6A and m5C lncRNA modifications in cancer.

Cusenza V, Tameni A, Neri A, Frazzi R Front Oncol. 2023; 13:1063636.

PMID: 36969033 PMC: 10033960. DOI: 10.3389/fonc.2023.1063636.

Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies.

Zhao A, Zhou H, Yang J, Li M, Niu T Signal Transduct Target Ther. 2023; 8(1):71.

PMID: 36797244 PMC: 9935927. DOI: 10.1038/s41392-023-01342-6.

References

Kim M, Yahng S, Kwon A, Park J, Jeon Y, Yoon J . Mutation in TET2 or TP53 predicts poor survival in patients with myelodysplastic syndrome receiving hypomethylating treatment or stem cell transplantation. Bone Marrow Transplant. 2015; 50(8):1132-4. DOI: 10.1038/bmt.2015.110. View

de Oliveira F, Miguel C, Lucena-Araujo A, de Lima A, Falcao R, Rego E . FISH analysis for TET2 deletion in a cohort of 362 Brazilian myeloid malignancies: correlation with karyotype abnormalities. Med Oncol. 2013; 30(1):483. DOI: 10.1007/s12032-013-0483-1. View

Meola N, Pizzo M, Alfano G, Surace E, Banfi S . The long noncoding RNA Vax2os1 controls the cell cycle progression of photoreceptor progenitors in the mouse retina. RNA. 2011; 18(1):111-23. PMC: 3261733. DOI: 10.1261/rna.029454.111. View

Gangaraju V, Lin H . MicroRNAs: key regulators of stem cells. Nat Rev Mol Cell Biol. 2009; 10(2):116-25. PMC: 4118578. DOI: 10.1038/nrm2621. View

Link D . Molecular genetics of AML. Best Pract Res Clin Haematol. 2012; 25(4):409-14. PMC: 3513694. DOI: 10.1016/j.beha.2012.10.002. View

Zhang X, Zhou Y, Mehta K, Danila D, Scolavino S, Johnson S . A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. J Clin Endocrinol Metab. 2003; 88(11):5119-26. DOI: 10.1210/jc.2003-030222. View

Langemeijer S, Kuiper R, Berends M, Knops R, Aslanyan M, Massop M . Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet. 2009; 41(7):838-42. DOI: 10.1038/ng.391. View

Heuston E, Lemon K, Arceci R . The Beginning of the Road for Non-Coding RNAs in Normal Hematopoiesis and Hematologic Malignancies. Front Genet. 2012; 2:94. PMC: 3268643. DOI: 10.3389/fgene.2011.00094. View

Kino T, Hurt D, Ichijo T, Nader N, Chrousos G . Noncoding RNA gas5 is a growth arrest- and starvation-associated repressor of the glucocorticoid receptor. Sci Signal. 2010; 3(107):ra8. PMC: 2819218. DOI: 10.1126/scisignal.2000568. View

10.

Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M . Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009; 114(1):144-7. PMC: 2710942. DOI: 10.1182/blood-2009-03-210039. View

11.

Khoury H, Suarez-Saiz F, Wu S, Minden M . An upstream insulator regulates DLK1 imprinting in AML. Blood. 2010; 115(11):2260-3. DOI: 10.1182/blood-2009-03-212746. View

12.

Guttman M, Amit I, Garber M, French C, Lin M, Feldser D . Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature. 2009; 458(7235):223-7. PMC: 2754849. DOI: 10.1038/nature07672. View

13.

Delhommeau F, Dupont S, Valle V, James C, Trannoy S, Masse A . Mutation in TET2 in myeloid cancers. N Engl J Med. 2009; 360(22):2289-301. DOI: 10.1056/NEJMoa0810069. View

14.

Pantoja C, de Los Rios L, Matheu A, Antequera F, Serrano M . Inactivation of imprinted genes induced by cellular stress and tumorigenesis. Cancer Res. 2005; 65(1):26-33. View

15.

Metzeler K, Maharry K, Radmacher M, Mrozek K, Margeson D, Becker H . TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2011; 29(10):1373-81. PMC: 3084003. DOI: 10.1200/JCO.2010.32.7742. View

16.

Bennett J, Catovsky D, Daniel M, Flandrin G, GALTON D, Gralnick H . Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985; 103(4):620-5. DOI: 10.7326/0003-4819-103-4-620. View

17.

Miyoshi N, Wagatsuma H, Wakana S, Shiroishi T, Nomura M, Aisaka K . Identification of an imprinted gene, Meg3/Gtl2 and its human homologue MEG3, first mapped on mouse distal chromosome 12 and human chromosome 14q. Genes Cells. 2000; 5(3):211-20. DOI: 10.1046/j.1365-2443.2000.00320.x. View

18.

Zawlik I, Vaccarella S, Kita D, Mittelbronn M, Franceschi S, Ohgaki H . Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: a population-based study. Neuroepidemiology. 2008; 32(1):21-9. DOI: 10.1159/000170088. View

19.

Quagliata L, Matter M, Piscuoglio S, Arabi L, Ruiz C, Procino A . Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. Hepatology. 2013; 59(3):911-23. PMC: 3943759. DOI: 10.1002/hep.26740. View

20.

Benetatos L, Hatzimichael E, Dasoula A, Dranitsaris G, Tsiara S, Syrrou M . CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes. Leuk Res. 2009; 34(2):148-53. DOI: 10.1016/j.leukres.2009.06.019. View